Drug Trial Radar · NCT01672476
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jul 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
293
Actual
Start
Apr 2012
Primary completion
Mar 2013
Study completion Apr 2013
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Bucheon St. Mary's Hospital; Konyang University Hospital; Korea University Anam Hospital; National Health Insurance Service Ilsan Hospital; Daegu Fatima Hospital; Dong-A University; Soon Chun Hyang University; Asan Medical Center; Gangnam Severance Hospital; Severance Hospital; Ulsan University Hospital; Kangbuk Samsung Hospital; Sejong General Hospital; Ewha Womans University Mokdong Hospital; Jeju National University Hospital; Hallym University Medical Center; Hanyang University
- First posted
- Aug 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension
Conditions
- Hypertension
Interventions
PlaceboDrug
Placebo
ValsartanDrug
Valsartan 80mg
FimasartanDrug
Fimasartan 30mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- the difference of sitting DBPTime frame: After 8 weeks from baseline visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.